Table 3:
Cancer treatment exposures for participants in the CCSS survivor cohort who received or registered on the wait-list for an organ transplantation (n=170)
| Survivors needing kidney transplantation (n=71) | |||
|---|---|---|---|
| Demographic Characteristics | |||
| Age at Cancer Diagnosis (median, IQR) in years | 2 (<1–9) | ||
| Age at Transplantation (median, IQR) in years | 25 (20–35) | ||
| Years from Cancer Diagnosis to Transplantation (median, IQR) | 21 (17–29) | ||
| Years after Wait-List or Transplantation for participants alive at end of follow-up (median, IQR) | 9 (5–14) | ||
| Years after Wait-List or Transplantation for participants dead at end of follow-up (median, IQR) | 7 (1–10) | ||
| Diagnosis | N | Percent | |
| Kidney tumor | 33 | 46·5% | |
| Acute lymphoblastic leukemia | 9 | 12·7% | |
| Acute myeloid and other leukemia | 4 | 5·6% | |
| Non-Hodgkin lymphoma | 8 | 11·3% | |
| Neuroblastoma | 7 | 9·9% | |
| Bone cancer | 7 | 9·9% | |
| Soft tissue sarcoma | 2 | 2·8% | |
| Central nervous system tumor | 1 | 1·4% | |
| Cancer treatment | N | Percent | |
| Cisplatin | No | 59 | 93·7% |
| Yes | 4 | 6·3% | |
| Ifosfamide | No | 59 | 93·7% |
| Yes | 4 | 6·3% | |
| Methotrexate (IV/IM) | No | 55 | 87·3% |
| Yes | 8 | 12·7% | |
| Nephrectomy | No | 39 | 61·9% |
| (all unilateral) | Yes | 24 | 38·1% |
| Mean Kidney Radiation Dose*† (Gy) | None | 26 | 41·3% |
| > 0 to 10 | 18 | 28·6% | |
| > 10 to 15 | 8 | 12·7% | |
| > 15 to 20 | 9 | 14·3% | |
| > 20 | 2 | 3·2% | |
| TBI | No | 59 | 93·7% |
| Yes | 4 | 6·3% | |
| treatment exposure data availability: complete (n=61), partial (n=4), none (n=6) | |||
| Survivors needing heart transplantation (n=62) | |||
| Demographic Characteristics | |||
| Age at Cancer Diagnosis (median, IQR) in years | 6 (3–11) | ||
| Age at Transplantation (median, IQR) in years | 28 (21–32) | ||
| Years from Cancer Diagnosis to Transplantation (median, IQR) | 17 (13–26) | ||
| Years after Wait-List or Transplantation for participants alive at end of follow-up (median, IQR) | 11 (6–20) | ||
| Years after Wait-List or Transplantation for participants dead at end of follow-up (median, IQR) | 1 (0–5) | ||
| Diagnosis | N | Percent | |
| Bone cancer | 15 | 24·2% | |
| Acute lymphoblastic leukemia | 8 | 12·9% | |
| Acute myeloid and other leukemia | 6 | 9·7% | |
| Hodgkin lymphoma | 12 | 19·4% | |
| Non-Hodgkin lymphoma | 10 | 16·1% | |
| Kidney tumor | 7 | 11·3% | |
| Soft tissue sarcoma | 3 | 4·8% | |
| Neuroblastoma | 1 | 1·6% | |
| Cancer treatment | N | Percent | |
| Anthracyclines | None | 9 | 17·0% |
| (mg/m2) | >0 to 150 | 3 | 5·7% |
| >150 to 300 | 4 | 7·5% | |
| >300 to 450 | 16 | 30·2% | |
| >450 | 21 | 39·6% | |
| Cisplatin | No | 53 | 94·6% |
| Yes | 3 | 5·4% | |
| Cyclophosphamide | None | 27 | 50·0% |
| (mg/m2) | >0 to 10000 | 10 | 18·5% |
| >10000 to 20000 | 12 | 22·2% | |
| >20000 | 5 | 9·3% | |
| Mean Heart Radiation Dose* (Gy) | None | 10 | 18·9% |
| >0 to 10 | 25 | 47·2% | |
| > 10 to 20 | 3 | 5·7% | |
| > 20 to 30 | 4 | 7·5% | |
| > 30 | 11 | 20·8% | |
| TBI | No | 52 | 98·1% |
| Yes | 1 | 1·9% | |
| treatment data availability: complete (n=52), partial (n=5), none (n=5) | |||
| Survivors needing liver transplantation (n=24) | |||
| Demographic Characteristics | |||
| Age at Cancer Diagnosis (median, IQR) in years | 6 (4–9) | ||
| Age at Transplantation (median, IQR) in years | 37 (25–38) | ||
| Years from Cancer Diagnosis to Transplantation (median, IQR) | 27 (20–29) | ||
| Years after Wait-List or Transplantation for participants alive at end of follow-up (median, IQR) | 6 (1–20) | ||
| Years after Wait-List or Transplantation for participants dead at end of follow-up (median, IQR) | 1 (0–3) | ||
| Diagnosis | N | Percent | |
| Acute lymphoblastic leukemia | 8 | 33·3% | |
| Acute myeloid and other leukemia | 3 | 12·5% | |
| Bone cancer | 4 | 16·7% | |
| Soft tissue sarcoma | 4 | 16·7% | |
| Kidney tumor | 3 | 12·5% | |
| Non-Hodgkin lymphoma | 1 | 4·2% | |
| Neuroblastoma | 1 | 4·2% | |
| Cancer treatment | N | Percent | |
| Dactinomycin | No | 12 | 57·1% |
| Yes | 9 | 42·9% | |
| Busulfan | No | 21 | 100·0% |
| Yes | 0 | 0·0% | |
| Cyclophosphamide | None | 5 | 25·0% |
| (mg/m2) | >0 to 10000 | 12 | 60·0% |
| >10000 to 20000 | 2 | 10·0% | |
| >20000 | 1 | 5·0% | |
| Melphalan | No | 21 | 100·0% |
| Yes | 0 | 0·0% | |
| Methotrexate (IV/IM) | No | 11 | 52·4% |
| Yes | 10 | 47·6% | |
| Max Abdomen Tumor Radiation Dose* (Gy) | None | 8 | 42·1% |
| >0 to 20 | 6 | 31·6% | |
| > 20 | 5 | 26·3% | |
| TBI | No | 18 | 94·7% |
| Yes | 1 | 5·3% | |
| treatment data availability: complete (n=19), partial (n=2), none (n=3) | |||
| Survivors needing lung transplantation (n=13) | |||
| Demographic Characteristics | |||
| Age at Cancer Diagnosis (median, IQR) in years | 12 (<1–16) | ||
| Age at Transplantation (median, IQR) in years | 30 (27–37) | ||
| Years from Cancer Diagnosis to Transplantation (median, IQR) | 21 (14–29) | ||
| Years after Wait-List or Transplantation for participants alive at end of follow-up (median, IQR) | 5 (1–15) | ||
| Years after Wait-List or Transplantation for participants dead at end of follow-up (median, IQR) | 3 (1–4) | ||
| Diagnosis | N | Percent | |
| Acute lymphoblastic leukemia | 3 | 23·1% | |
| Acute myeloid and other leukemia | 2 | 15·4% | |
| Hodgkin lymphoma | 3 | 23·1% | |
| Kidney tumor | 2 | 15·4% | |
| Non-Hodgkin lymphoma | 1 | 7·7% | |
| Neuroblastoma | 1 | 7·7% | |
| Central nervous system tumor | 1 | 7·7% | |
| Cancer treatment | N | Percent | |
| Carmustine | No | 8 | 72·7% |
| Yes | 3 | 27·3% | |
| Bleomycin | No | 10 | 90·9% |
| Yes | 1 | 9·1% | |
| Busulfan | No | 11 | 100·0% |
| Yes | 0 | 0·0% | |
| Lomustine | No | 11 | 100·0% |
| Yes | 0 | 0·0% | |
| Cisplatin | No | 10 | 90·9% |
| Yes | 1 | 9·1% | |
| Cyclophosphamide | None | 4 | 44·4% |
| (mg/m2) | >0 to 10000 | 4 | 44·4% |
| >10000 to 20000 | 1 | 11·1% | |
| >20000 | 0 | 0·0% | |
| Methotrexate (IV/IM) | No | 7 | 63·6% |
| Yes | 4 | 36·4% | |
| Mean Lung Radiation Dose*† (Gy) | None | 2 | 18·2% |
| >0 to 10 | 4 | 36·4% | |
| >10 | 5 | 45·5% | |
| TBI | No | 9 | 81·8% |
| Yes | 2 | 18·2% | |
| treatment data availability: complete (n=11), partial (n=0), none (n=2) | |||
IQR – interquartile range, IV – intravenous, IM – intramuscular, TBI – total body irradiation.
*
Radiation received as TBI is included in the organ-specific dose calculations.
†
If the right and left kidneys (lungs) received different amounts of radiation, the survivor was classified based on the kidney (lung) with the lesser degree of radiation exposure.